Trial Profile

Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapies; An Observational Prospective Study

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 28 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Durvalumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Trastuzumab (Primary)
Indications Infusion related reaction
Focus Adverse reactions
Acronyms MINUTE

Most Recent Events

21 May 2025 Planned End Date changed from 1 Dec 2024 to 1 Dec 2026.
21 May 2025 Planned primary completion date changed from 1 Jul 2024 to 1 Jul 2026.
05 Mar 2024 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com